Cephalosporin therapeutics in cystic fibrosis.
Cephalosporins modified at the C-3 and C-7 positions of the cephem-nucleus have high antimicrobial activity and are safe. With evolution through first, second, and third generations, they have gained increasing gram-negative activity, but often at the expense of potency against gram-positive organisms. All third-generation cephalosporins have some intrinsic anti-Pseudomonas activity, indicating their potential benefit in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Rational therapy in this clinical setting requires recognition of the pharmacodynamic and pharmacokinetic idiosyncrasies intrinsic to this patient population. When these priorities are recognized, only two of the available agents, cefsulodin and ceftazidime, appear to be of any therapeutic value. Both agents have been evaluated extensively in the treatment of acute pulmonary exacerbation in cystic fibrosis, and both have been found to be safe and effective.
D002441:Cefsulodin / Q000627:therapeutic use; D002442:Ceftazidime / Q000627:therapeutic use; D002511:Cephalosporins / Q000378:metabolism / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003550:Cystic Fibrosis / Q000150:complications* / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008171:Lung Diseases / Q000188:drug therapy / Q000209:etiology; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000209:etiology; D013329:Structure-Activity Relationship
D002511:Cephalosporins; D002442:Ceftazidime; D002441:Cefsulodin